Medical information and pharmacovigilance are two different life sciences functions that meet at the same front door. Medical information answers a healthcare professional’s scientific questions; pharmacovigilance monitors and reports drug safety. The connection: every inquiry has to be screened for adverse events, and any safety finding routed to the safety team quickly.
Medical information vs. pharmacovigilance: the short answer
Both functions sit inside Medical Affairs or Safety, and both deal with what happens after a product reaches patients. But they answer different questions. Medical information exists to give healthcare professionals (HCPs) accurate answers. Pharmacovigilance exists to keep track of a product’s safety profile. The two only feel tangled because a single phone call can trigger both at once.
What is medical information?
Medical information is the function that responds to unsolicited scientific and technical questions from HCPs — dosing, interactions, off-label use, device technique, and the evidence behind a product. Each of those questions is a medical information request (MIR), and the job is to answer it accurately, from approved sources, and on the record.
What is pharmacovigilance?
Pharmacovigilance (PV) is, in the World Health Organization’s words, the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Its job isn’t to answer questions — it’s to watch a product’s safety over its whole lifecycle.
When a safety event is identified, PV teams document it as an Individual Case Safety Report (ICSR) and, where required, report it to regulators through systems such as the FDA’s FAERS in the United States or EudraVigilance in the European Union. Adverse events are one input to that work; PV data is broader, covering overdose, misuse, medication errors, exposure in pregnancy, and lack of effect, whether or not harm actually occurred.
The key difference
Put side by side, the two functions rarely overlap in purpose — only in intake.
| Medical Information | Pharmacovigilance | |
|---|---|---|
| Purpose | Answer HCP scientific and technical questions | Detect, assess, and report product safety |
| Trigger | An unsolicited question | An adverse event or safety signal |
| Output | An accurate, referenced response | A case safety report (ICSR) |
| Typically owned by | Medical Information / Medical Affairs | Drug Safety / Pharmacovigilance |
| Regulatory frame | Off-label response rules, promotion separation | ICH E2, GVP, expedited & periodic reporting |
Where they overlap: the adverse event inside a medical inquiry
Here’s the part that trips teams up. An HCP rarely calls to “file an adverse event.” They call to ask a question — and somewhere in that question is a sentence like “my patient developed a rash after the second dose.” That’s a medical inquiry and a potential safety report in the same breath.
Because medical information is often the first human contact point, MI agents are usually the first to hear about a safety event. That makes screening non-negotiable: every inquiry has to be checked for adverse events, and anything that qualifies has to be handed to pharmacovigilance without delay. Serious, unexpected cases are frequently subject to expedited reporting — commonly within 15 calendar days — while other cases follow periodic schedules. The exact clock depends on the region and the case, but the principle is universal: safety information can’t sit in an inbox.
How to route an HCP inquiry correctly
A simple way to think about routing:
- Is it a question? It goes to medical information for a response.
- Does it describe a patient event or side effect? It also goes to pharmacovigilance as a potential safety report — even if the HCP only wanted an answer.
- Is it a problem with the product itself (a cracked device, a packaging defect)? That’s a product complaint, which follows its own quality workflow.
Many inquiries fall into more than one bucket at once. The goal isn’t to force a single label — it’s to make sure nothing that qualifies as a safety event is missed, mislabeled, or delayed.
Why your intake system decides whether this works
On paper, the split is clean. In practice, it lives or dies at intake. If inquiries arrive across phone, email, and web forms with no consistent capture, a safety event buried in a routine dosing question is easy to miss — and a missed report is a compliance problem, not just an admin one.
That’s why the system that captures medical inquiries matters as much as the teams behind it. MedInfosys brings every HCP inquiry — form, email, phone, and portal — into one case record with a complete audit trail, so agents can flag safety information at the point of intake and nothing slips through the cracks between medical information and pharmacovigilance.
Frequently asked questions
What is the difference between medical information and pharmacovigilance?
Medical information answers healthcare professionals’ scientific and technical questions about a product, while pharmacovigilance monitors, assesses, and reports the product’s safety. They are separate functions that intersect at intake, because a single inquiry can contain both a question and a safety event.
Is an adverse event a medical information request?
Not exactly. A medical information request is a question; an adverse event is a safety occurrence. They often arrive together — an HCP asking a question may also describe a side effect — which is why medical information teams screen every inquiry for adverse events.
Who handles an adverse event reported to medical information?
The medical information agent captures and flags it, then routes it to the pharmacovigilance or drug safety team, which assesses it and files any required regulatory report. Medical information is frequently the first point of contact, but pharmacovigilance owns the safety reporting.
How quickly must an adverse event be reported?
It depends on the region and the case. Serious, unexpected events are often subject to expedited reporting, commonly within 15 calendar days, while less serious cases follow periodic reporting schedules under frameworks such as ICH E2 and Good Pharmacovigilance Practices.
Do medical information and pharmacovigilance use the same system?
Often no — they use different specialized systems, and safety information is handed from one to the other. What matters is that the intake process reliably captures and routes safety events so nothing is lost in the handoff.
What is an ICSR?
An Individual Case Safety Report (ICSR) is the structured record pharmacovigilance teams create for a single adverse event case, used to assess safety and, where required, report to regulators through systems like FAERS or EudraVigilance.
Capture every inquiry — and every safety signal inside it
The line between medical information and pharmacovigilance is clear on paper; the risk is in the handoff. See how MedInfosys captures HCP inquiries across every channel and keeps a full audit trail, so safety information is flagged and routed the moment it arrives — request a demo to see it with your own workflow.
